Skip to content
10-K

Annual Report

PARATEK PHARMACEUTICALS, INC.

0001564590-22-009957

← back to feed
Filed
Mar 14, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Feb 28, 2022 52.37M sh
Net Income FY 2021 · Dec 31, 2021 −$32.25M
Net Income FY 2021 · Sep 30, 2021 −$18.2M
Net Income FY 2021 · Jun 30, 2021 $9.72M
Net Income FY 2021 · Mar 31, 2021 −$18.35M
Net Income FY 2021 · Dec 31, 2020 −$25.01M
Net Income FY 2021 · Dec 31, 2020 −$96.54M
Net Income FY 2021 · Sep 30, 2020 −$20.86M
Net Income FY 2021 · Jun 30, 2020 −$23.06M
Net Income FY 2021 · Mar 31, 2020 −$27.62M
Operating Income FY 2021 · Dec 31, 2021 −$27.28M
Operating Income FY 2021 · Sep 30, 2021 −$13.72M
Operating Income FY 2021 · Jun 30, 2021 $14.09M
Operating Income FY 2021 · Mar 31, 2021 −$14.22M
Operating Income FY 2021 · Dec 31, 2020 −$17.53M
Operating Income FY 2021 · Dec 31, 2020 −$75.5M
Operating Income FY 2021 · Sep 30, 2020 −$15.95M
Operating Income FY 2021 · Jun 30, 2020 −$18.45M
Operating Income FY 2021 · Mar 31, 2020 −$23.58M
Revenue FY 2021 · Dec 31, 2021 $31.8M
Revenue FY 2021 · Sep 30, 2021 $24.45M
Revenue FY 2021 · Jun 30, 2021 $57.49M
Revenue FY 2021 · Mar 31, 2021 $16.43M
Revenue FY 2021 · Dec 31, 2020 $16.02M
Revenue FY 2021 · Dec 31, 2020 $46.92M
Revenue FY 2021 · Sep 30, 2020 $13.66M
Revenue FY 2021 · Jun 30, 2020 $9.33M
Revenue FY 2021 · Mar 31, 2020 $7.92M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$103.42M
Long Term Debt FY 2021 · Dec 31, 2020 $250.47M
Cash And Equivalents FY 2021 · Dec 31, 2020 $105.16M
Current Liabilities FY 2021 · Dec 31, 2020 $23.95M
Total Liabilities FY 2021 · Dec 31, 2020 $279.11M
Current Assets FY 2021 · Dec 31, 2020 $164.12M
Total Assets FY 2021 · Dec 31, 2020 $176.85M
Sga Expense FY 2021 · Dec 31, 2020 $89.86M
Cost Of Revenue FY 2021 · Dec 31, 2020 $8.65M
Stockholders Equity FY 2021 · Dec 31, 2019 −$39.65M